Wangjun Liao
Impact in
- Cancer Research top 0.5%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
Papers in
- Oncology 62
- Cancer Immunotherapy and Biomarkers 29
- Colorectal Cancer Treatments and Studies 14
-
- Gastric Cancer Management and Outcomes 23
- Lung Cancer Treatments and Mutations 12
- Co-authors
- Yulin Liao (125 shared papers)Jianping Bin (120 shared papers)Min Shi (58 shared papers)Rui Zhou (30 shared papers)Dongqiang Zeng (25 shared papers)Na Huang (24 shared papers)Li Sun (20 shared papers)Jingwen Zhang (14 shared papers)
- Journals
- Oncotarget (7 papers)Theranostics (6 papers)Scientific Reports (5 papers)Cell Death and Disease (5 papers)Cancer Letters (5 papers)
- Partner nations
- ChinaSwedenUnited States
In The Last Decade
Wangjun Liao
230 papers receiving 11.7k citations
Wangjun Liao's Hit Papers
Peers
Comparison fields: 5 of 121
- Cancer Research 1.9k
- Oncology 3k
- Otorhinolaryngology 522
- Pulmonary and Respiratory Medicine 2.4k
- Molecular Biology 2.8k
Countries citing papers authored by Wangjun Liao
This map shows the geographic impact of Wangjun Liao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wangjun Liao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wangjun Liao more than expected).
Fields of papers citing papers by Wangjun Liao
This network shows the impact of papers produced by Wangjun Liao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wangjun Liao. The network helps show where Wangjun Liao may publish in the future.
Co-authors
The 25 scholars most cited alongside Wangjun Liao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 235 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | IOBR: Multi-Omics Immuno-Oncology Biological Research to Decode Tumor Microenvironment and Signatures Hit paper breakdown → | 2021 | 869 |
| 2 | Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures Hit paper breakdown → | 2019 | 739 |
| 3 | 2019 | 378 | |
| 4 | Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial Hit paper breakdown → | 2022 | 371 |
| 5 | Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial Hit paper breakdown → | 2021 | 306 |
| 6 | Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer Hit paper breakdown → | 2023 | 266 |
| 7 | Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02) Hit paper breakdown → | 2021 | 256 |
| 8 | 2017 | 244 | |
| 9 | 2019 | 244 | |
| 10 | 2019 | 224 | |
| 11 | 2021 | 204 | |
| 12 | 2018 | 202 | |
| 13 | 2018 | 196 | |
| 14 | 2018 | 182 | |
| 15 | 2021 | 173 | |
| 16 | 2021 | 170 | |
| 17 | 2017 | 169 | |
| 18 | 2018 | 158 | |
| 19 | Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma Hit paper breakdown → | 2023 | 156 |
| 20 | 2015 | 128 |
About Wangjun Liao
Wangjun Liao is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Cardiology and Cardiovascular Medicine, having authored 235 papers that have together received 11.8k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (29 papers), Gastric Cancer Management and Outcomes (23 papers), Congenital heart defects research (21 papers), Cardiac Fibrosis and Remodeling (18 papers), Colorectal Cancer Treatments and Studies (14 papers), Circular RNAs in diseases (13 papers), Lung Cancer Treatments and Mutations (12 papers) and Ultrasound and Hyperthermia Applications (12 papers). The work is most often cited by research in Cancer Research (1.9k citations), Oncology (3k citations), Otorhinolaryngology (522 citations), Pulmonary and Respiratory Medicine (2.4k citations) and Molecular Biology (2.8k citations). Wangjun Liao has collaborated with scholars based in China, Sweden and United States. Frequent co-authors include Yulin Liao, Jianping Bin, Min Shi, Rui Zhou, Dongqiang Zeng, Na Huang, Li Sun, Jingwen Zhang, Huiying Sun and Lin Li. Their work appears in journals such as Oncotarget, Theranostics, Scientific Reports, Cell Death and Disease and Cancer Letters.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.